Avant Brands Reports Record-Breaking Results in Fiscal Year 2023
KELOWNA, BC / ACCESSWIRE / February 29, 2024 / Avant Brands Inc (TSX:AVNT)(OTCQX:AVTBF)(FRA:1BU0) ("Avant" or the "Company"), a leading producer...
Year: 2024
Moderna to Host Fifth Annual Investor Event For Vaccines and Business Updates on March 27, 2024
CAMBRIDGE, MA / ACCESSWIRE / February 29, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host its fifth...
AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update
Company continues progress across Ampligen® clinical development programs Growing body of promising data demonstrates Ampligen’s potential to address multiple high-value...
SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing
The SCI- 210 treatment is now available at clinical site for autism spectrum disorder clinical trial in pediatric patients, in...
Yield10 Bioscience Reports that Proprietary Varieties of Winter Camelina Show Tolerance to Commonly Used Herbicides in First Field Tests
-Herbicide tolerance is critical to planting the Camelina crop on large acreage for the biofuel and omega-3 oil marketsWOBURN, Mass.,...
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors
Application based on Phase 3 DeFi trial in which nirogacestat significantly improved progression-free survival and objective response rate compared to...
Independent Lab Confirms Immunogenicity and Protection with IMUNON’s IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5
Murine Study by the Wistar Institute Builds Upon Favorable Results Previously Reported by IMUNON With its Prototype PlaCCine Vaccine Modality...
CytoDyn Announces FDA Has Lifted Clinical Hold
Webcast to Provide Company Update on March 5, 2024 VANCOUVER, Washington, Feb. 29, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:...
Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC
sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBCPrecedent-setting submission includes data from post-marketing...
TOMI Environmental Announces Additional iHP Custom Engineered System Installation Contracted for California
FREDERICK, Md., Feb. 29, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in...
Autonomix Signs Key Clinical Agreements in Preparation to Begin March 2024 Human Clinical Trial
Proof-of-concept (PoC) human clinical trial targeting multi-billion-dollar pancreatic cancer market through transvascular RF ablation Agreements represent final steps needed in...
Kineta Announces Restructuring and Exploration of Strategic Alternatives
SEATTLE, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of...
Cronos Group Reports 2023 Fourth Quarter and Full-Year Results¹
Ended 2023 with approximately $862 million in cash and short-term investments Commenced sales to Australian partner Launched award-winning Lord Jones®...
Achieve Life Sciences Reaches Agreement with the FDA on Long-Term Cytisinicline Exposure Data Requirements for NDA Submission
Open-label exposure trial expected to initiate in Q2’24 with NDA filing anticipated in 1H 2025SEATTLE and VANCOUVER, British Columbia, Feb....
Ocean Biomedical (NASDAQ: OCEA) Announces Joint Venture Partner, Virion Therapeutics to Present Their First Clinical Study Data as an Accepted Late Breaker Presentation at 2024 APASL Global Liver Meeting
Providence, RI, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company which endeavors to accelerate the...
SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time
NEW YORK, Feb. 29, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a...
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024
Management to host conference call on Thursday, March 7, 2024, at 8:30 a.m. ET FLORHAM PARK, N.J., Feb. 29, 2024...
Nanox and Beilinson Hospital Announce Collaboration to Study Diagnostic Capabilities of Nanox.ARC for Detection of Lung and Chest Diseases
First patients in clinical study at Beilinson Hospital were scanned with the Nanox.ARC, a stationary X-ray system that produces 3D...
Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results
— Record revenues of $675 million in 2023 — — Full-year GAAP net income of $42 million and adjusted EBITDA...
Clinical Study Results Involving Spryng, a PetVivo Holdings, Inc. Product, Presented at the Veterinary Orthopedic Society Annual Conference in Lake Tahoe, California
MINNEAPOLIS, MN, US, Feb. 29, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the “Company” or “PetVivo")...